Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose 4.4% during trading on Thursday . The stock traded as high as $12.89 and last traded at $12.80, with a volume of 403,419 shares. The stock had previously closed at $12.26.

VNDA has been the subject of several recent analyst reports. Brean Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, April 27th. Jefferies Group reissued a “buy” rating and issued a $15.00 price objective on shares of Vanda Pharmaceuticals in a research note on Saturday, May 7th. Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Finally, Piper Jaffray Cos. restated a “buy” rating and issued a $16.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, July 28th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $16.83.

The firm’s market capitalization is $554.04 million. The company has a 50-day moving average of $11.58 and a 200-day moving average of $9.56.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.12. The firm had revenue of $36.02 million for the quarter, compared to the consensus estimate of $36.03 million. Vanda Pharmaceuticals’s quarterly revenue was up 30.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.13) earnings per share. On average, equities analysts predict that Vanda Pharmaceuticals Inc. will post ($0.61) EPS for the current year.

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. Bank of Montreal Can boosted its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 23.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,208,918 shares of the biopharmaceutical company’s stock after buying an additional 228,074 shares during the period. Bank of Montreal Can owned 2.82% of Vanda Pharmaceuticals worth $11,255,000 at the end of the most recent reporting period.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.